Abstract: ROS kinase is one of the last two remaining orphan RTKs with a yet unidentified ligand. The normal functions of human ROS kinase in different body tissues have not been fully identified so far. However, the ectopic expression, as well as the production of variable mutant forms of ROS kinase has been reported in a number of cancers, such as glioblastoma multiforme, and non-small cell lung cancer, suggesting a role for ROS kinase in deriving such tumors. It is thought also that c-ROS gene may have a role in some cardiovascular diseases, and the fact that homozygous male mice targeted against c-ROS gene are healthy but infertile, has inspired researchers to think about ROS inhibition as a method for development of new male contraceptives. The recent discovery of new selective and potent inhibitors for ROS kinase, along with the development of new specific diagnostic methods for the detection of ROS-fusion proteins, raises the importance of using these selective inhibitors for targeting ROS mutations as a new method for treatment of cancers harboring such genes. This review focuses on the ectopic expression of ROS and its fusion proteins in different cancer types, and highlights the importance of targeting these proteins for treatment of substantial cancers. It describes also the recent advances in the field of ROS kinase inhibition, and the potential clinical applications of ROS kinase inhibitors.
INTRODUCTION
Receptor tyrosine kinases (RTKs) are important players in the process of signal transduction and cellular communication. They act as the cell surface receptors for a number of important growth factors and hormones. 1 In addition to the vital role of these RTKs as regulators for normal cellular processes, they also have another dark side presented by their key roles in the initiation and progression of a number of cancers. In these types of cancers, gene translocations resulting in kinase fusion proteins with constitutive and uncontrolled activity are so common.
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It's much helpful also in providing new selective and sensitive diagnostic tools for identifying patients harboring such gene mutations or translocations allowing for their early treatment before progression of the cancer into a more complicated phase. Referring again to the example of Bcr-Abl translocation in CML patients, it's noteworthy to mention that the development and approval of Gleevec (Imatinib mesylate, STI-571) 5 as the first kinase inhibitor to be used as an anticancer drug that selectively targets Bcr-Abl fusion protein for treatment of CML, has opened a new stream in the field of development of new selective therapeutics for treatment of certain cancers. This drug is the first of a new class of anti-proliferative agents designed to interfere with the signaling pathways that derive the growth of tumor cells. The development of this drug represents a significant advance over the classical therapies for CML. The use of conventional chemotherapies and radiation which lack the selectivity of targeting cancerous cells, results in serious side effects and is often of limited usefulness, since it fails to specifically target the underlying causes of malignancies. Accordingly, there is a continuous desire to identify new gene translocations or mutations that are responsible for the production of fusion or mutant proteins implicated in the progression of human cancers.
There are 58 RTKs in humans that belong to 20 distinct families, 1,2 among these kinases is 'ROS kinase', which is one of the last two remaining orphan RTKs, since its ligand is yet unidentified. During the last 25 years, extensive work has been made for the identification and characterization of ROS RTK and its encoding gene, however, the first and the only review available so far about ROS kinase was published recently by Acquaviva et al. 6 That review has addressed the different roles of ROS kinase in normal and cancerous tissues, its distribution in different body organs and hypothesized some possible methods for the discovery of its unidentified ligand. In this review we focus mainly on the mutagenic transformations in ROS gene and the resulted fusion proteins as possible targets for new selective anticancer drugs. This review addresses also the recent discovery of selective ROS kinase inhibitors, 7, 8 and the possible and potential applications for such inhibitors.
5 was found to be expressed in a tissue specific manner with c-ROS transcripts of varying sizes in different tissues.
The obtained transcripts were isolated from lungs, kidneys, heart and testis. 20 The in vivo expression pattern of ROS in mice was also determined, where transient ROS expression was found during development, in kidneys, lungs and intestine. 26 It was found also that ROS mRNA is present in the caput segment of the epididymis of adult mice. 27 The expression was found to be restricted to the epithelial cells of the epididymis and is initially detected at the onset of regionalization of the caput epididymis. 27 In humans, ROS was found to be expressed throughout the human epididymis at varying levels, while absent from the proximal caput. 30 A recent northern blot analysis of RNA isolated from various adult human organs has determined that the highest ROS expression was detected in the lungs. Size variants were also detected in RNA isolated from placenta and skeletal muscle tissues. 6 The expression pattern of ROS in different organs suggests that it may play a role in the mature functions of these organs beyond the developmental role. It's important also to notice that usually cellular homologues to retroviral transforming genes play an important role in cellular growth and/or differentiation, and appear to have oncogenic potential that can be manifested after transduction by a retrovirus. The process of conversion from a normal proto-oncogene to a transforming oncogene involves either mutation and/or degradation.
glioblastoma derived cell lines at high levels (ranging from 10 to 60 transcripts per cell), while not expressed at all or expressed minimally in the remaining cell lines. 49 Moreover, no expression of ROS gene was observed in normal brain tissues, thus, the high level of ROS expression in glioblastoma seems specific.
In all of the tested glioblastoma cell lines, the c-ROS encoded transcript was found to be 8.3 Kb in size, except for the cell line U-118MG, where its size was found to be only 4 Kb, which suggests that the glioblastoma cell line U-118MG produces a high level of an altered (mutated) ROS-encoded protein. These results were contradicted by the findings of Wu and Chikaraishi 53 where they failed to detect elevated ROS expression in a survey of 25 specimens taken from patients with astrocytomas and glioblastoma multiformes (GBM) of all histological grades.
However, they did not rule out the possibility of presence of small clones in the tumor, in which ROS is expressed in significant levels, but diluted with the larger population of non-ROS or low-ROS expressing cells. They expected also that ROS expression could be induced when the astrocytomas or glioblastomas were adapted in tissue culture.
However, the over-expression of ROS in surgical specimens was proved later by two independent analyses using RNase protection and cDNA hybridization techniques, where high levels of ROS expression in 33% and 40% of glioblastoma surgical tumors has been reported. 50, 51 The failure of ROS detection in lower grade astrocytomas suggests however that ROS may play a role in tumor progression rather than initiation. 50 The expression of ROS in meningiomas was also evaluated by complete reverse transcription and polymerase chain reaction (RT-PCR) assays. 54 ROS was found to be expressed at high levels in meningiomas (55%, 17 of 33) while not expressed in nonneoplastic brain samples. Recently, the expression of ROS in malignant glioma tumors was also evaluated. 52 ROS was found to be over-expressed in 25% of low grade and 30% of malignant gliomas. From a total of 231 astrocytic glioma samples, it was found that 23% (11 of 47) of grade II, 17% (13 of 78) of grade III and 29% (31 of 106) of glioblastoma multiformes expressed ROS.
ROS in non-small cell lung cancer (NSCLC)
In a large scale survey of tyrosine kinase activity in lung cancer, tyrosine kinase signaling was characterized across 41 NSCLC cell lines and over 150 NSCLC tumors. 55 Profiles of phosphotyrosine signaling were generated and analyzed to identify known oncogenic kinases. Surprisingly, ROS kinase was of the top ten RTKs found in both cell lines and tumors. RTKs in this survey were ranked according to phosphorylation rank (phosphorylation level/sample). The results revealed that ROS kinase was highly expressed in one tumor sample and in the NSCLC cell line (HCC78). 55 In addition to ROS over-expression in these samples, PTPN11 (protein tyrosine phosphatase, non-receptor type 11) and IRS-2 (Insulin receptor substrate-2) previously reported to be important downstream effectors of ROS in glioblastoma 56 were found to be highly phosphorylated in ROS expressing samples. 55 Furthermore, several microarray analyses of tumor specimens revealed significantly elevated ROS expression levels in 20 -30% of patients with NSCLC. [57] [58] [59] Contrasting for brain tumors, elevated ROS expression in lung tumors was observed in both early and late stage tumors, 60 suggesting a key role for ROS in the initiation or development rather than progression of lung tumors.
ROS in stomach, breast, liver, colon and kidney cancers
c-ROS gene was found to be up-regulated in gastric cancer induced by oral administration of N-methyl-N'-nitro-Nnitrosoguanidine (MNNG) in rat. 61 ROS gene was one of six genes found to be persistently up-regulated after 4
weeks from MNNG treatment. ROS gene was found also to be over-expressed (in a number of other genes) in fibroadenoma samples taken from breast tumors of 5 different patients. It was found to be expressed at levels more than 2 fold higher than those in normal tissues.
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In liver, the induction of hepatic progenitor cells activation in a rat model of liver injury was found to be associated with over-expression of ROS. In addition, over-expression of ROS was also observed in a rat hepatoma cell line. 63, 64 Recently, a global sequencing survey of all tyrosine kinases in 254 cell lines revealed three new ROS mutations in two colon adenocarcinoma and one kidney carcinoma cell lines. 65 
MUTANT FORMS OF ROS
The most common methods for RTKs activation in cancer cells are genomic arrangements, exemplified by gene amplifications, chromosomal translocations, inversions and deletions. 
v-ROS and Mcf3
The transforming gene product, P68 gag-ROS , encoded by UR2 sarcoma virus genome is a rearranged product of the chicken c-ROS gene. 12 Studies made on v-ROS have revealed that the 3'-change of v-ROS has little effect on activation of the transforming potential of c-ROS, while 5'-truncation (deleting all but 6 amino acids of the extracellular domain) and fusion to gag are required for activation of c-ROS transforming activity, although this activity is not as potent as that of v-ROS. 66 Combination of 5'-truncation and the 3 amino acids insertion in the TM domain is sufficient to convert c-ROS into an oncogene as potent as v-ROS. 66 To further explore the role of this 3 amino acids insertion in v-ROS, this sequence was deleted and the transforming function and signal transduction of the mutant protein were investigated. 67 The obtained results revealed that the three amino acids deletion has no effect on the protein tyrosine activity of v-ROS, but this deletion results greatly in reduced transforming and mitogenic potency, as well as an altered protein modification and substrate interaction, despite the fact that the cytoplasmic domain of the mutant protein is unaltered. 67 In mammalian species, an activated form of human c-ROS gene, Mcf3, has been isolated from the DNA of the human carcinoma cell line MCF-7, using a tumorigenicity assay. 68, 69 Mcf3 probably arose during gene transfer from a normal human c-ROS gene, by the loss of a putative extracellular domain. In this transformation, all of the amino acids (except only 8) of the putative extracellular domain of c-ROS are thought to be replaced by another unknown piece of DNA. 69 The point of fusion between cellular and viral sequences in v-ROS gene was found to be located in an analogous position to that in Mcf3 fusion, leading to the loss of most of the putative extracellular domain.
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The point of divergence between the normal and U-118MG c-ROS genes was located to that portion of c-ROS that encodes the junction between the putative extracellular and trans-membrane domains (TM domain). 49 Interestingly, this point of rearrangement in U-118MG DNA was found to be very close to the point of rearrangement that created v-ROS and Mcf3 genes. 15 After about 15 years, the molecular details for this genetic 
Figure 1
This was the first example for a fusion RTK protein that resulted from an intra-chromosomal deletion, and it represents the first fusion RTK protein isolated from a human astrocytoma. In order to ascertain the frequency of 
SLC34A2-ROS and CD74-ROS
Relative to other cancer types, only a limited number of gene translocations and mutant proteins have been reported in lung cancer, such as the t(15;19) translocation involving notch3. 78 A transforming fusion gene "EML4-ALK" has been recently identified by Soda et al. 79 in 6.7% of smoker Japanese patients with non-small cell lung cancer. This chimeric gene which was generated by a small inversion within the chromosome 2 short arm encodes a 1059 amino acids fusion protein. 80 However, the first reported translocations in human NSCLC involving protein kinases were those of ROS. 55, 81, 82 The first translocation, SLC34A2-ROS, resulted from the fusion of c-ROS to the transmembrane solute carrier protein (SLC34A2) was discovered in the NSCLC cell line HCC78. 55, 81 This translocation between chromosomes 4q15 and 6q22 produced two fusion protein variants, that combine the Nterminus of sodium-dependent phosphate transporter protein, with the transmembrane and kinase domains of the proto-oncogene RTK ROS ( Fig. 2A) . The resulting SLC34A2-ROS fusion proteins, which are 724 amino acids (long variant) and 621 amino acids (short variant) are expected to retain kinase activity, and to derive the proliferation and survival of a subset of human NSCLC tumors, in which the fusion protein is expressed.
SLC34A2 is a phosphate transporter protein that is expressed in human lung and small intestine, and which has Na-dependent activity. 83 Defects in SLC34A2 expression and/or activity have been previously reported in ovarian cancer. 84 In order to verify the role of this genetic fusion in the initiation and development of the cancerous cells harboring it, the ability of two different siRNAs, targeted against c-ROS, to inhibit HCC78 cellular growth was evaluated. 55 Both of the two tried siRNAs were found to be effective in reducing ROS protein expression, and inducing cell death in HCC78 cells, demonstrating a strict dependence on ROS signaling for HCC78 cells survival.
Figure 2
The second ROS fusion (CD74-ROS) was identified in a c-ROS positive NSCLC tumor, where a translocation between chromosomes 5q32 and 6q22 resulting in the fusion of the N-terminus of CD74 to ROS at the typical site of the short transcript of SLC34A2-ROS fusion created a fusion protein (703 amino acids length) with two transmembrane domains, as in SLC34A2-ROS fusion, (Fig. 2B) . 55, 82 CD74 is a type II trans-membrane protein that functions as the receptor for the macrophage migration inhibitory factor (MIF) immune cytokine. 85 CD74 functions also as an MHC (major histo-compatibility complex) class II chaperone protein which plays a critical role during peptide presentation to CD4-positive lymphocytes. 86 
ROS SIGNALING
It has been demonstrated by the limited number of studies made on ROS kinase, that ROS activates several signaling pathways important for cell growth and survival. However, this kind of studies about ROS signaling is so limited, because of lack of knowledge about ROS ligand. To date, it was found that ROS activation involves these downstream activators and effectors:
STAT3
Signal transducers and activators of transcription (STATs) are transcription factors that regulate many aspects of cell growth, survival and differentiation. They are involved in cytokine and growth factor receptor induced gene expression. These transcription factors are activated by tyrosine phosphorylation, and they were found to be activated in a number of primary tumors, leading to increased angiogenesis, enhanced survival of tumors and immuno-suppression. 88, 89 The seven mammalian STAT family members identified so far are STAT1, STAT2, STAT3, STAT4, STAT5 (STAT5A and STAT5B), and STAT6. It's noteworthy to mention that the constitutive activation of STAT3 has been reported in malignant brain tumors, 90 and that STAT3 activation has been associated with resistance to chemo-and radiotherapy, which is a characteristic feature in CNS cancers. It has been also reported that ROS activates predominantly STAT3 in NIH-3T3 cells, and that STAT3 is required for ROSanchorage-independent growth. 91 Accordingly, the activated function of STAT3 seems to be important for the establishment and maintenance of ROS-induced cell transformation.
VAV3
VAV proteins are guanine-nucleotide exchange factors for Rho GTPases that regulate actin dynamics and gene 12 be constitutive and independent of ROS activation. The inhibition of VAV/Rho GTPase signaling was found to be successful in suppressing ROS-induced colony formation in chicken embryo fibroblasts (CEFs) and anchorageindependent growth in NIH-3T3 cells. 100
PI3K/AKT/m-TOR signaling cascade
The Phosphoinositide-3 kinase (PI3K) signaling pathway is a key regulator in a number of cellular processes, such as cellular proliferation, differentiation and apoptosis. 101, 102 The AKT kinase, is a major downstream target of PI3K, and is an important mediator in cell growth and function. 103, 104 The activation of PI3K/AKT pathway was found to be an important event for ROS-induced transformation, and the inhibition of PI3K signaling pathway was proved to significantly diminish the ability of ROS to induce colony formation and anchorage-independent growth of fibroblasts. 100, 105 The activation of PI3K by ROS is thought to be mediated by IRS-1 scaffold protein, since the activity of PI3K was significantly decreased using SIR-1 antibodies. 105, 106 It has been demonstrated also that 
SHP-1
The SH2-domain containing protein tyrosine phosphatase SHP-1, 108,109 is expressed in hematopoietic, and at lower levels, in epithelial cells. It has been speculated that the defects in sperm maturation in ROS -/-mice (with a targeted mutation of c-ROS) 27 and me v mice (with 80-90% reduction of SHP-1 activity) 110 might be related at the molecular level. This speculation was based on the hypothesis that, if ROS and SHP-1 interact in a common signal transduction pathway, impairment of the epidermal function might result from inactivation of either gene. Indeed, the molecular analysis has revealed that ROS binds and activates SHP-1 and that SHP-1 strongly binds ROS, and regulates ROS signaling in a negative manner, through a -ve feed back inhibitory mechanism. 111 ROS and SHP-1 are co-expressed in epididymal epithelium, and elevated phosphorylation of ROS in the epididymis of me v mice suggests that ROS signaling is under control of SHP-1 in vivo. The interaction between SHP-1 and ROS was found to be mediated by high affinity binding of the SHP-1 N-terminal SH2 domain, and ROS phosphopeptides binding sites pY2267 and pY2327. 112 These two phosphopeptides binding sites were found to be differentially employed in binding to SHP-1, where pY2267 was found to be involved in ligand-dependent stimulation of complex formation, while pY2327 mediates constitutive ligand-independent SHP-1 association. 112 A number of linear and cyclic phosphopeptides related to the pY2267 binding site of ROS kinase have been synthesized and evaluated as ligands for the amino terminal SH2 domain of the protein tyrosine phosphatase SHP-1, in order to be used as activators for ROS down-regulation. 113, 114 The synthesized derivatives displayed much lower potencies for the stimulation of SHP-1 activity, but higher affinities relative to ROS pY2267, recommending their use as SHP-1 competitive inhibitors rather than agonists for phosphatase activity. 
SHP-2
In addition to binding to SHP-1, ROS kinase was found to bind and activate the SH2-domain containing protein tyrosine phosphatae SHP-2. 56 PTPN11, the gene encoding for SHP-2, was found to be mutated in a number of hematological malignancies, [115] [116] [117] and solid tumors. 118 The constitutively active SHP-2 is hence considered to be an oncogene, and the source of its oncogenicity comes from its ability to regulate the activation of a number of RTKs to the RAS/Raf/MEK/ERK signaling cascade. [119] [120] [121] It was found also that the oncogenic activity of FIG-ROS fusion protein is mediated through phosphorylation of SHP-2, suggesting that SHP-2 activation is a crucial event in FIG-ROS transformation. 56 Furthermore, in SLC34A2-ROS and CD74-ROS fusion proteins harboring cells, the phosphopeptides corresponding to the tyrosyl phosphorylation sites of SHP-2 were found to be up-regulated. 55 These results strongly suggest that the activation of SHP-2 tyrosine phosphatase is an important signaling mediator for the constitutive activity of ROS kinase.
c-ROS: A GENETIC VARIANT FOR CARDIOVASCULAR (CV) DISEASES
As mentioned before, the physiological roles of c-ROS gene expression in different body organs have not been fully characterized. However, a number of studies have correlated between c-ROS and the incidence of different cardiovascular diseases. A large-scale, gene-centric association study made on 11,053 single nucleotide polymorphisms (SNPs) from 6891 genes has suggested that the risk of myocardial infarction (MI) was associated with specific genes, so far not linked to atherosclerosis. 122 These genes encode the cytoskeletal protein paladin (PALLD), a taste receptor (TAS2R50), an olfactory receptor (OR13G1), a zinc finger protein (ZNF627) and ROS.
However, a number of subsequent studies failed to prove such association between MI and these genetic variants, [123] [124] [125] emphasizing the high potential of false positive results obtained from the initial study, and indicating the necessity for continued refinement of cardiovascular genetic methodologies for clinical applications.
In two other studies applied to Japanese individuals, links have been proposed between the polymorphism of c-ROS gene (in a number of other genes) and restenosis 126 and hypertension. 127 In the first study, polymorphism of BCHE, GPX1 and c-ROS genes were found to be independently associated with in-stent restenosis after bare-metal stenting of coronary arteries, suggesting a genetic risk of these gene-determinants in in-stent restenosis. 126 In the second study, polymorphism in ABCA1 and c-ROS genes were reported in hypertensive Japanese patients, suggesting the possibility of using these genotypes for the prediction of the genetic risk for hypertension. 127 The genetic risk of atherothrombotic cerebral infarction was also correlated to c-ROS gene polymorphism, where in two different studies, 128, 129 c-ROS gene was among a number of other genes whose polymorphism was proposed to be informative for the prediction of the genetic risk of atherothrombotic cerebral infarction.
These frequent observations of c-ROS gene in a number of different CV diseases, and in every time among a number of varying genes, suggest a real possible role for ROS in one or more of these CV diseases. Furthermore, the reasonable expression of ROS reported in heart 20 and epithelial tissues [26] [27] [28] [29] provides another reason for considering a role of this gene in the CV system. However, the lack of ROS-ligand identity is a key difficulty in the full understanding of its role in different body tissues, and the identification of such ligand may provide important answers for such questions.
c-ROS GENE AND INFERTILITY
Transgenic mice targeted for c-ROS gene are fertile when heterozygous (HET) but infertile when homozygous (Knockout, KO). 27, 130 The infertility of male homozygous c-ROS knockout mice, inspite of normal mating contrasts with the effectiveness of cauda epididymal sperm in fertilizing ova in vitro, 27 and the most obvious explanation of these results would be that the motility of sperms from the knockout animals is impaired, so that they fail to reach the oocytes in vivo. 131 c-ROS knockout mice lack the prepubertal differentiation of the epididymal initial segment, and a high proportion of sperms released from the cauda epididymis of these mice display sever tail angulations at the midpiece. 130 These flagellar angulations were thought to be the reason behind the reduced sperm numbers in the oviduct of mated females, and the failure to fertilize in vivo.
However, because the majority but not all the mature epididymal sperms from the knockout mice exhibit tail angulations, these findings suggest the possibility of some motile sperms with straight tails migrating into the oviduct, so the complete infertility of knockout males remain unexplained. One crucial aspect of natural fertilization is the binding of sperms to the oviductal epithelium for survival and prevention of precocious capacitation. [132] [133] [134] [135] [136] [137] Because the initial epididymal segment is active in the synthesis of specific epididymal secretions, and this segment fails to differentiate in the sterile c-ROS knockout males, it is possible that sperms from these males are not normally endowed and consequently incapable of normal interaction with the oviductal epithelium and fail to reach the oocyte in a potentially fertilizing state. 131 Hence, the infertility of c-ROS knockout male mice can be explained by the inability of sperms to enter the oviduct, as a result of the bent tails of the majority of them compromised by their inability to effectively interact with the oviductal epithelium. Because flagellar angulations usually reflect a defect in volume regulation, 130, 138 and the capacity for sperm volume regulation is developed during maturation in the epididymis, 139 it was important to verify modifications in luminal fluid of c-ROS knockout male mice. A number of studies have revealed variable changes and abnormalities in the luminal fluid of these mice. [140] [141] [142] It was found that c-ROS homozygous knockout mice don't express the glutamate transporter excitatory amino acid carrier 1 (EAA1) mRNA in the caput, and since glutamate is used as a an osmolyte in somatic cells, the lack of EAA1 may disrupt osmolyte balance in the proximal epididymal lumen, affecting sperm maturation and the development of sperm volume regulatory mechanisms. 140 A decrease in the Na-hydrogen exchanger NHE2 in the caput, and NHE3 in the cauda, associated with increase in luminal fluid pH in the c-ROS knockout male mice was also reported. 141 In another study, an increased K + ion concentration in cauda epididymal fluid was observed. 142 These abnormal changes in sperm content which result in maturational abnormalities in volume regulation might have a compromising effect to sperm tail angulations, leading finally to c-ROS knockout male mice sterility.
The much concern about c-ROS gene and its role in the infertility of c-ROS knockout mice suggests the possibility of future using of ROS inhibitors as male contraceptives. However, a number of important points should be considered. First of all, the distinct differences between the human and mice epididymis, and the corresponding variations in ROS expression pattern in the epididymis of each of them may lead to a different effect of ROS inhibition in humans, which is not necessarily a complete infertility. The other important point to be considered is that the changes in the sperms of c-ROS knockout mice which made them to be infertile are thought to be caused by maturational defects in the epididymis before puberty. Hence, the effect of ROS-inhibition on the fertility of mature wild male mice, and consequently on adult humans, would likely be significantly different.
ROS-INHIBITION FOR CANCER TREATMENT
It could be concluded from what is described in the previous sections that ROS kinase (with its fusion forms) is an important deriver for a number of cancers, and that the targeting and inhibition of its activity could provide more efficient and selective solutions for the treatment of substantial cancers derived by it. The ability to diagnose and identify the cancer types harboring c-ROS mutations is as important as the development of selective and potent inhibitors for ROS RTK. The ability to identify, as early as possible, cancers that are derived by a mutant ROS kinase will greatly assist in determining the suitable therapeutic, or combination of therapeutics, that is most appropriate for the patient, thus helping to avoid description of inhibitors targeting other kinases that are not, in fact, the primary signaling molecule deriving the cancer.
For example; although targeted EGFR inhibitors are currently approved for the treatment of NSCLS, 87 it's anticipated that this therapy might be partially or wholly ineffective against those patients having tumors in which, mutant ROS kinase (rather than or in addition to EGFR) is expressed and deriving the disease in whole or in part.
Instead, these tumors are most likely to respond to inhibitors for the mutated ROS kinase.
Moreover; a recent discovery has proved a high potential risk if the demethylating agent, 5-aza-2'-deoxycitidine 
ROS INHIBITORS AND POTENTIAL USES
The discovery of selective ROS kinase inhibitors was an important step to verify a number of theoretical speculations about ROS, and also to test for the applicability of these inhibitors in the clinical uses presumed for ROS inhibitors. Since the approval of the first kinase inhibitor, Gleevec, 5 for treatment of chronic myeloid leukemia, a vast growth has been noticed in the field of drug discovery for the development of new selective kinase inhibitors targeted against mutant kinases. A number of inhibitors such as Staurosporine, AST-487 and PP 2 have been reported to inhibit ROS kinase, and even with high potency in some of them (as in case of Staurosporine, IC 50 = 0.9 nM), but all these inhibitors were unfortunately highly unselective (Fig. 3) . 144 The lack of selectivity in these inhibitors prohibited their clinical uses against any of the kinases inhibited by them in most of the cases (Table I ).
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Figure 3 Table I 
Recent discovery of selective and potent ROS kinase inhibitors
The first selective and potent ROS kinase inhibitors have been recently developed by our group. 7, 8 A new hit pyrazole derivative (KIST301072) was discovered during screening of new potential kinase inhibitors prepared in our laboratory over a large panel of kinases (Fig. 3) . KIST301072 was initially screened over a panel of 45 different kinases at a single dose concentration of 10 µM. At this concentration, a 94% inhibition of the enzymatic activity of ROS kinase was observed, while the inhibition in activity was below 30% in all of the other kinases. 7 The compound was then further tested in a 10-dose IC 50 mode and showed an IC 50 value of 199 nM for ROS kinase (Table II) .
Table II
Following the discovery of this compound, we have synthesized a series of structurally related compounds and evaluated their capacity to inhibit ROS kinase. 8 A new equipotent structurally simplified hit was evolved in this study, where KIST301080 showed in Fig. (3) was found to inhibit ROS kinase activity with an IC 50 value of 209 nM.
Potential clinical applications of ROS kinase inhibitors
As showed in table III; a number of potential clinical applications and uses are speculated for ROS kinase inhibitors.
At the top of these applications is the ability of these inhibitors to treat and inhibit tumors derived by ROS kinase.
Accordingly; it is very important now to evaluate the ability of these inhibitors to inhibit the growth of cancer celllines that are over-expressing c-ROS or harboring ROS mutations, such as GBM U-118MG and NSCLC HCC78 cell lines. Generally, it is anticipated that compounds which can inhibit the activity of wild ROS would be also It would be also interesting to use these inhibitors to test for the sensitivity and applicability of the newly engineered reporter construct designed to test for the ability of potential inhibitors to turn-off ROS kinase activity. 143 The emergence of these new potent and selective inhibitors could also open the way for the verification of the ability of ROS inhibitors to be used as male contraceptives. The treatment of wild adult mice with ROS inhibitors and evaluating the ability of the inhibitors to produce infertility temporarily would be of great impact on the field of development of male contraceptives. Similarly, the doubt about a genetic role for ROS in a number of cardiovascular diseases could be also verified by testing the capability of ROS inhibitors to reverse and cure such diseases.
Table III

OTHER METHODS FOR ROS INHIBITION
In addition to small molecular kinase inhibitors, the inhibition of ROS kinase could be achieved by some other alternative ways. These alternatives include the use of ROS-kinase targeted antibodies that specifically bind to critically catalytic or binding domains required for ROS activity, and inhibit the kinase by blocking access of ligands, substrates or secondary molecules. It's important however to note that the use of antibodies that target the extracellular domain of ROS would be useless in inhibiting mutant ROS-fusion proteins, since in these fusion proteins the extracellular domain is totally or partly lost. Instead, the antibodies targeting the newly fused part (from FIG, SLC34A2 or CD74 for example) could be helpful in inhibiting the activity of these fusion proteins.
Another possible alternative is the use of small interfering RNA (siRNA), which inhibits gene translation and hence activity of ROS kinase, through the process of RNA interference. RNA interference and selective silencing of target protein expression by introduction of exogenous small double strand RNA molecules comprising sequence complementary to mRNA encoding the target protein has been well described. [146] [147] [148] [149] [150] The use of siRNA against ROS has been already proved to be effective in ceasing ROS expression and inducing cell death in HCC78 NSCLC cells, 55 as previously described in this review. The inhibition of ROS signaling could be also achieved by indirect ways, through the interference with its downstream effectors, such as STAT3, VAV3, SHP-1, SHP-2, and PI3K/AKT/mTOR signaling mediators. As mentioned previously, the inhibitions of m-TOR 56 and VAV/Rho
GTPase signaling 100 were successful in suppressing ROS signals and subsequently inhibiting ROS-induced cell growth. Accordingly, the inhibitors for such signaling downstream effectors could be useful, alone or in combination with specific ROS inhibitors, for the silencing of amplified c-ROS signaling in different diseases.
CONCLUSION
The 
